Published in J Biol Chem on October 27, 1995
Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol (2010) 8.87
HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol (2011) 6.23
Harmful molecular mechanisms in sepsis. Nat Rev Immunol (2008) 6.03
The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest (2001) 5.49
HMGB1: endogenous danger signaling. Mol Med (2008) 4.02
Microbial pathogen-induced necrotic cell death mediated by the inflammasome components CIAS1/cryopyrin/NLRP3 and ASC. Cell Host Microbe (2007) 3.52
The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol (2001) 3.43
Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J (2003) 3.29
New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J (2001) 3.04
The inflammatory response to cell death. Annu Rev Pathol (2008) 2.85
The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest (2005) 2.80
HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol (2012) 2.75
Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol (2004) 2.75
RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med (2009) 2.56
Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Ther Adv Musculoskelet Dis (2013) 2.39
NLRP3 (NALP3, Cryopyrin) facilitates in vivo caspase-1 activation, necrosis, and HMGB1 release via inflammasome-dependent and -independent pathways. J Immunol (2009) 2.39
A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc Natl Acad Sci U S A (2002) 2.35
Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol Med (2006) 2.27
The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res (2010) 2.19
Targeting HMGB1 in inflammation. Biochim Biophys Acta (2009) 2.11
Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest (2001) 2.07
Accessory molecules for Toll-like receptors and their function. Nat Rev Immunol (2012) 2.00
Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J Cell Biol (2007) 1.98
Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem (2008) 1.97
Pathogenesis of malaria and clinically similar conditions. Clin Microbiol Rev (2004) 1.87
Advanced glycation end product recognition by the receptor for AGEs. Structure (2011) 1.84
Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci U S A (1997) 1.82
High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity. J Biol Chem (2010) 1.79
HMGB1 in cancer: good, bad, or both? Clin Cancer Res (2013) 1.79
Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol (2005) 1.75
High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism. Diabetes (2010) 1.74
The receptor for advanced glycation end products (RAGE) and the lung. J Biomed Biotechnol (2010) 1.68
Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia (2009) 1.66
Articular chondrocytes express the receptor for advanced glycation end products: Potential role in osteoarthritis. Arthritis Rheum (2005) 1.65
Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res (2012) 1.61
Alarmins link neutrophils and dendritic cells. Trends Immunol (2009) 1.61
Receptor for advanced glycation end products (RAGE) on iNKT cells mediates lung ischemia-reperfusion injury. Am J Transplant (2013) 1.59
Diet restriction inhibits apoptosis and HMGB1 oxidation and promotes inflammatory cell recruitment during acetaminophen hepatotoxicity. Mol Med (2010) 1.54
The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. Biochemistry (2007) 1.51
Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med (Berl) (2009) 1.51
Activation of poly(ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus. J Biol Chem (2007) 1.51
Structural basis for ligand recognition and activation of RAGE. Structure (2010) 1.50
Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care (2007) 1.50
Ligands of the receptor for advanced glycation end products, including high-mobility group box 1, limit bacterial dissemination during Escherichia coli peritonitis. Crit Care Med (2010) 1.47
Blockade of high mobility group box-1 protein attenuates experimental severe acute pancreatitis. World J Gastroenterol (2006) 1.44
The anti-inflammatory effects of heat shock protein 72 involve inhibition of high-mobility-group box 1 release and proinflammatory function in macrophages. J Immunol (2007) 1.43
The Role of High Mobility Group Box 1 Protein (HMGB1) in the Immunopathology of Experimental Pulmonary Tuberculosis. PLoS One (2015) 1.43
Danger signals activating the immune response after trauma. Mediators Inflamm (2012) 1.40
Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci U S A (1996) 1.40
CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns. Trends Immunol (2009) 1.39
TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J (2010) 1.37
Temporal and spatial patterns of endogenous danger signal expression after wound healing and in response to lymphedema. Am J Physiol Cell Physiol (2011) 1.37
Role of advanced glycation end products in cellular signaling. Redox Biol (2014) 1.36
RAGE signaling in inflammation and arterial aging. Front Biosci (Landmark Ed) (2009) 1.35
Endogenous signals released from necrotic cells augment inflammatory responses to bacterial endotoxin. Immunol Lett (2007) 1.35
Bench-to-bedside review: The inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care (2008) 1.34
Transmission of cell stress from endoplasmic reticulum to mitochondria: enhanced expression of Lon protease. J Cell Biol (2002) 1.33
Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models. Mol Med (2011) 1.27
Inhibitor of NF-kappa B kinases alpha and beta are both essential for high mobility group box 1-mediated chemotaxis [corrected]. J Immunol (2010) 1.27
Hemorrhagic shock activation of NLRP3 inflammasome in lung endothelial cells. J Immunol (2011) 1.25
Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann Med (2009) 1.25
Astrocytic high-mobility group box 1 promotes endothelial progenitor cell-mediated neurovascular remodeling during stroke recovery. Proc Natl Acad Sci U S A (2012) 1.24
Amphoterin stimulates myogenesis and counteracts the antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding. Mol Cell Biol (2004) 1.24
Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules (2015) 1.23
Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J (2009) 1.23
Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol (2010) 1.22
Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int J Inflam (2013) 1.22
S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and release. J Biol Chem (2011) 1.22
Activated protein C inhibits high mobility group box 1 signaling in endothelial cells. Blood (2011) 1.22
TIRAP, an adaptor protein for TLR2/4, transduces a signal from RAGE phosphorylated upon ligand binding. PLoS One (2011) 1.21
High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice. J Clin Invest (2010) 1.21
HBV pathogenesis in animal models: recent advances on the role of platelets. J Hepatol (2007) 1.20
The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases. Mol Med (2014) 1.17
Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Ann N Y Acad Sci (2008) 1.17
High-mobility group protein box-1 and its relevance to cerebral ischemia. J Cereb Blood Flow Metab (2009) 1.16
The 1.5 Å crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding. J Biol Chem (2010) 1.16
RAGE: the beneficial and deleterious effects by diverse mechanisms of actions. Mol Cells (2011) 1.15
Scientific and clinical challenges in sepsis. Curr Pharm Des (2009) 1.14
Bench-to-bedside review: High-mobility group box 1 and critical illness. Crit Care (2007) 1.14
Molecular mechanisms of Ca(2+) signaling in neurons induced by the S100A4 protein. Mol Cell Biol (2006) 1.13
Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis. J Immunol (2008) 1.13
Damage-associated molecular patterns (DAMPs) in preterm labor with intact membranes and preterm PROM: a study of the alarmin HMGB1. J Matern Fetal Neonatal Med (2011) 1.13
An endothelial growth factor involved in rat renal development. J Clin Invest (1998) 1.12
RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med (2007) 1.11
S100A11, an dual mediator for growth regulation of human keratinocytes. Mol Biol Cell (2007) 1.11
RAGE expression in tumor-associated macrophages promotes angiogenesis in glioma. Cancer Res (2014) 1.08
Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia. Virology (2009) 1.07
Interacting neuroendocrine and innate and acquired immune pathways regulate neutrophil mobilization from bone marrow following hemorrhagic shock. J Immunol (2009) 1.07
HMGB1 acts in synergy with lipopolysaccharide in activating rheumatoid synovial fibroblasts via p38 MAPK and NF-κB signaling pathways. Mediators Inflamm (2013) 1.06
Characterization of RAGE, HMGB1, and S100beta in inflammation-induced preterm birth and fetal tissue injury. Am J Pathol (2009) 1.05
Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury. Immunol Lett (2008) 1.04
RAGE: a new frontier in chronic airways disease. Br J Pharmacol (2012) 1.04
HMGB1 increases permeability of the endothelial cell monolayer via RAGE and Src family tyrosine kinase pathways. Inflammation (2012) 1.02
High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4. Mol Med (2013) 1.02
Metabolism addiction in pancreatic cancer. Cell Death Dis (2014) 1.02
High-mobility group box-1 protein promotes granulomatous nephritis in adenine-induced nephropathy. Lab Invest (2010) 1.01
Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res (2013) 1.01
Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-kappaB. J Pathol (2009) 1.00
The role of high mobility group box 1 in innate immunity. Yonsei Med J (2014) 1.00
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res (1997) 665.31
The sequence of the human genome. Science (2001) 101.55
Comparative genomics of the eukaryotes. Science (2000) 26.62
Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med (2001) 12.38
RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell (1999) 8.55
The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J (2001) 7.97
The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ (2007) 7.74
Engineering the provitamin A (beta-carotene) biosynthetic pathway into (carotenoid-free) rice endosperm. Science (2000) 7.53
RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature (1996) 7.04
Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia (2006) 6.31
A potential vulnerability locus for schizophrenia on chromosome 6p24-22: evidence for genetic heterogeneity. Nat Genet (1995) 5.87
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet (2001) 5.80
Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem (1992) 5.60
The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet (1997) 5.55
Sites of specific B cell activation in primary and secondary responses to T cell-dependent and T cell-independent antigens. Eur J Immunol (1991) 5.38
Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase. Mol Cell (2001) 5.04
A kinase-cyclin pair in the RNA polymerase II holoenzyme. Nature (1995) 4.93
Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology (2001) 4.84
HCFA's racial and ethnic data: current accuracy and recent improvements. Health Care Financ Rev (2000) 4.67
Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev (2001) 4.47
CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology (2007) 4.24
Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci U S A (2000) 4.22
Sequence specificity in the dimerization of transmembrane alpha-helices. Biochemistry (1992) 4.19
An essential role in liver development for transcription factor XBP-1. Genes Dev (2000) 4.17
Comparative analysis of 1196 orthologous mouse and human full-length mRNA and protein sequences. Genome Res (1996) 4.11
The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature (2000) 4.00
Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med (1990) 3.93
Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci (2001) 3.85
Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther (2003) 3.85
Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem (1998) 3.77
Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem (1994) 3.73
Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A (1998) 3.72
The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia (2008) 3.69
Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene (2009) 3.64
Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem (1992) 3.64
Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int (2006) 3.64
A local alignment tool for very long DNA sequences. Comput Appl Biosci (1995) 3.58
Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat Genet (2001) 3.48
The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci U S A (1999) 3.43
The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ (2009) 3.43
Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet (1999) 3.39
Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway. Genes Dev (2000) 3.38
Mutation in the silencing gene SIR4 can delay aging in S. cerevisiae. Cell (1995) 3.37
Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med (1995) 3.32
CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity (2000) 3.28
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol (2000) 3.24
Influenza virus hemagglutinin and neuraminidase cytoplasmic tails control particle shape. EMBO J (1997) 3.23
BCL-6 protein is expressed in germinal-center B cells. Blood (1995) 3.18
The EGF-CFC protein one-eyed pinhead is essential for nodal signaling. Cell (1999) 3.15
Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol (1998) 3.13
A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J Biol Chem (1997) 3.12
Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med (1998) 3.05
Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol (1997) 3.03
Applications of network BLAST server. Methods Enzymol (1996) 3.03
Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res (1999) 2.87
Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci U S A (1999) 2.85
Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature (2001) 2.83
Physicochemical foundations and structural design of hydrogels in medicine and biology. Annu Rev Biomed Eng (2000) 2.73
A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control (2003) 2.67
Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature (1998) 2.65
Transmembrane TGF-alpha precursors activate EGF/TGF-alpha receptors. Cell (1989) 2.65
Association of an activator with an RNA polymerase II holoenzyme. Genes Dev (1995) 2.61
Mitochondrial genotype associated with longevity. Lancet (1998) 2.58
Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med (1989) 2.52
Hormonal changes in the grains of rice subjected to water stress during grain filling. Plant Physiol (2001) 2.52
Cellular mechanisms for developmental toxicity of chlorpyrifos: targeting the adenylyl cyclase signaling cascade. Toxicol Appl Pharmacol (1997) 2.42
Stoichiometric and steric principles governing repression by nuclear hormone receptors. Genes Dev (1997) 2.41
The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis (2003) 2.34
HIV knowledge and risk behaviour of female sex workers in Yunnan Province, China: potential as bridging groups to the general population. AIDS Care (2005) 2.34
Hypoxia-mediated induction of endothelial cell interleukin-1 alpha. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest (1992) 2.34
Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J Biol Chem (1997) 2.33
Angiogenesis inhibited by drinking tea. Nature (1999) 2.31
Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res (2000) 2.31
Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery (2001) 2.30
A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data. Pharmacogenomics J (2010) 2.30
An assessment of the potential for reducing future combat deaths through medical technologies and training. J Trauma (2002) 2.29
Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virol (2004) 2.26
Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin Chem (1999) 2.26
Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci (1999) 2.25
Analysis of heart rate variability demonstrates effects of development on vagal modulation of heart rate in healthy children. J Pediatr (1997) 2.24
Diffusion tensor imaging of the developing mouse brain. Magn Reson Med (2001) 2.20
Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res (1999) 2.19
Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides. J Appl Microbiol (2008) 2.19
The nitric oxide hypothesis of late preconditioning. Basic Res Cardiol (1998) 2.19
Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci U S A (1990) 2.18
Premelting at defects within bulk colloidal crystals. Science (2005) 2.15
Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. Immunity (2001) 2.11
Isolation and characterization of auxotrophic mutants of Legionella pneumophila that fail to multiply in human monocytes. Infect Immun (1988) 2.10
Robust relational parsing over biomedical literature: extracting inhibit relations. Pac Symp Biocomput (2002) 2.09
Excessive activation of the alternative complement pathway in autosomal dominant polycystic kidney disease. J Intern Med (2014) 2.06
Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb (1994) 2.05